MicroRNA-601 Enhances Osimertinib Sensitivity by Targeting Transient Receptor Potential Mucolipin 3 in Non-small Cell Lung Cancer Cells
Year: 2025
Type: article
Abstract: signaling, particularly via transient receptor potential mucolipin 3 (TRPML3; also known as MCOLN3), contributes to TKI resistance by promoting lysosomal exocytosis and drug efflux. Here, we investigated the regulatory role of microRNA-601 (miR-601) in modulating TRPML3 expression and its impact on osimertinib resistance in NSCLC. Bioinformatic predictions using the DIANA microT-CDS algorithm identified TRPML3 as a putative target of miR-601. Luciferase reporter assays confirmed direct binding of miR-601 to the TRPML3 3'-untranslated region. Functional assays were conducted with parental and osimertinib-resistant PC9 and HCC827 cells to evaluate the effects of miR-601 on TRPML3 expression, apoptosis, cell-cycle progression, and drug sensitivity. Osimertinib treatment led to a time-dependent miR-601 downregulation in NSCLC cells, and its basal expression remained suppressed in resistant sublines. miR-601 overexpression reduced TRPML3 protein levels, enhanced poly(ADP-ribose) polymerase cleavage, induced G0/G1 cell-cycle arrest, and restored osimertinib sensitivity. Similar effects were observed upon TRPML3 knockdown, supporting a TRPML3-dependent mechanism. Thus, miR-601 negatively regulates TRPML3 and modulated TKI responses in NSCLC cells. Restoring miR-601 expression may represent a promising therapeutic strategy for overcoming acquired osimertinib resistance by targeting TRPML3-mediated lysosomal signaling.
Source: Journal of Cancer Prevention
DOI: 10.15430/jcp.25.039
Authors: Mi Seong Kim, Mi Seong Kim, Min Seuk Kim, Min Seuk Kim
Institution: Wonkwang University
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: diamond
Awards: G1498186989, G5774662557
OpenAlex ID: W7116038560
FWCI:
Cites:
Cited by:
Related to:
